$ALT Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Altimmune, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Altimmune, Inc.. Get notifications about new insider transactions in Altimmune, Inc. for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
May 04 2021 | ALT | Altimmune, Inc. | Garg Vipin K | President and CEO | Payment of Exercise | F | 14.47 | 1,999 | 28,926 | 307,183 | 309.2 K to 307.2 K (-0.65 %) |
Mar 31 2021 | ALT | Altimmune, Inc. | Garg Vipin K | President and CEO | Payment of Exercise | F | 13.55 | 1,998 | 27,073 | 309,182 | 311.2 K to 309.2 K (-0.64 %) |
Mar 01 2021 | ALT | Altimmune, Inc. | Hodges Philip | Director | Sell | S | 16.08 | 6,000 | 96,480 | 8,731 | 14.7 K to 8.7 K (-40.73 %) |
Mar 01 2021 | ALT | Altimmune, Inc. | Garg Vipin K | President and CEO | Payment of Exercise | F | 15.94 | 1,998 | 31,848 | 311,180 | 313.2 K to 311.2 K (-0.64 %) |
Mar 01 2021 | ALT | Altimmune, Inc. | Venrock Healthcare Capital Par ... | 10% Owner | Option Exercise | J | 0.00 | 1,000,000 | 100 | 1,000,000 | |
Mar 01 2021 | ALT | Altimmune, Inc. | Venrock Healthcare Capital Par ... | 10% Owner | Sell | J | 0.00 | 1,000,000 | 0 | 3,500,000 | 4.5 M to 3.5 M (-22.22 %) |
Feb 01 2021 | ALT | Altimmune, Inc. | Garg Vipin K | President and CEO | Payment of Exercise | F | 14.28 | 2,353 | 33,601 | 312,123 | 314.5 K to 312.1 K (-0.75 %) |
Jan 04 2021 | ALT | Altimmune, Inc. | Garg Vipin K | President and CEO | Payment of Exercise | F | 11.30 | 3,025 | 34,183 | 314,476 | 317.5 K to 314.5 K (-0.95 %) |
Dec 11 2020 | ALT | Altimmune, Inc. | Schafer Klaus | Director | Buy | P | 11.99 | 2,000 | 23,980 | 8,900 | 6.9 K to 8.9 K (+28.99 %) |
Dec 02 2020 | ALT | Altimmune, Inc. | Hodges Philip | Director | Sell | S | 13.54 | 1,227 | 16,614 | 0 | 1.2 K to 0 (-100.00 %) |
Dec 02 2020 | ALT | Altimmune, Inc. | Hodges Philip | Director | Sell | S | 12.00 | 2,500 | 30,000 | 14,731 | 17.2 K to 14.7 K (-14.51 %) |
Dec 02 2020 | ALT | Altimmune, Inc. | GILL JOHN | Director | Sell | S | 11.92 | 8,425 | 100,426 | 11,199 | 19.6 K to 11.2 K (-42.93 %) |
Dec 02 2020 | ALT | Altimmune, Inc. | Garg Vipin K | President and CEO | Payment of Exercise | F | 12.23 | 2,243 | 27,432 | 317,501 | 319.7 K to 317.5 K (-0.70 %) |
Nov 13 2020 | ALT | Altimmune, Inc. | Schafer Klaus | Director | Sell | S | 9.91 | 10,150 | 100,587 | 6,900 | 17.1 K to 6.9 K (-59.53 %) |
Nov 13 2020 | ALT | Altimmune, Inc. | Pisano Wayne | Director | Sell | S | 9.90 | 10,352 | 102,485 | 8,498 | 18.9 K to 8.5 K (-54.92 %) |
Nov 13 2020 | ALT | Altimmune, Inc. | Harris Matthew Scott | Director | Sell | S | 10.02 | 4,015 | 40,230 | 4,069 | 8.1 K to 4.1 K (-49.67 %) |
Oct 16 2020 | ALT | Altimmune, Inc. | SAYARE MITCHEL | Director | Option Exercise | M | 0.00 | 25,275 | 0 | 0 | |
Oct 16 2020 | ALT | Altimmune, Inc. | SAYARE MITCHEL | Director | Buy | M | 0.00 | 25,275 | 0 | 26,363 | 1.1 K to 26.4 K (+2,323.07 %) |
Oct 16 2020 | ALT | Altimmune, Inc. | GILL JOHN | Director | Option Exercise | M | 0.00 | 16,850 | 0 | 0 | |
Oct 16 2020 | ALT | Altimmune, Inc. | GILL JOHN | Director | Buy | M | 0.00 | 16,850 | 0 | 19,624 | 2.8 K to 19.6 K (+607.43 %) |
Oct 16 2020 | ALT | Altimmune, Inc. | Pisano Wayne | Director | Option Exercise | M | 0.00 | 16,850 | 0 | 0 | |
Oct 16 2020 | ALT | Altimmune, Inc. | Pisano Wayne | Director | Buy | M | 0.00 | 16,850 | 0 | 18,850 | 2 K to 18.9 K (+842.50 %) |
Oct 16 2020 | ALT | Altimmune, Inc. | Drutz David | Director | Option Exercise | M | 0.00 | 16,850 | 0 | 0 | |
Oct 16 2020 | ALT | Altimmune, Inc. | Drutz David | Director | Buy | M | 0.00 | 16,850 | 0 | 17,543 | 693 to 17.5 K (+2,431.46 %) |
Oct 16 2020 | ALT | Altimmune, Inc. | Schafer Klaus | Director | Option Exercise | M | 0.00 | 16,850 | 0 | 0 | |
Oct 16 2020 | ALT | Altimmune, Inc. | Schafer Klaus | Director | Buy | M | 0.00 | 16,850 | 0 | 17,050 | 200 to 17.1 K (+8,425.00 %) |
Oct 16 2020 | ALT | Altimmune, Inc. | Hodges Philip | Director | Option Exercise | M | 0.00 | 16,850 | 0 | 0 | |
Oct 16 2020 | ALT | Altimmune, Inc. | Hodges Philip | Director | Buy | M | 0.00 | 16,850 | 0 | 36,306 | 19.5 K to 36.3 K (+86.61 %) |
Oct 02 2020 | ALT | Altimmune, Inc. | Garg Vipin K | President & CEO | Payment of Exercise | F | 13.20 | 2,015 | 26,598 | 321,759 | 323.8 K to 321.8 K (-0.62 %) |
Sep 28 2020 | ALT | Altimmune, Inc. | Hodges Philip | Director | Option Exercise | A | 12.03 | 25,500 | 306,765 | 25,500 | |
Sep 28 2020 | ALT | Altimmune, Inc. | SAYARE MITCHEL | Director | Option Exercise | A | 12.03 | 25,500 | 306,765 | 25,500 | |
Sep 28 2020 | ALT | Altimmune, Inc. | Pisano Wayne | Director | Option Exercise | A | 12.03 | 25,500 | 306,765 | 25,500 | |
Sep 28 2020 | ALT | Altimmune, Inc. | Jorkasky Diane | Director | Option Exercise | A | 12.03 | 9,500 | 114,285 | 9,500 | |
Sep 28 2020 | ALT | Altimmune, Inc. | Drutz David | Director | Option Exercise | A | 12.03 | 25,500 | 306,765 | 25,500 | |
Sep 28 2020 | ALT | Altimmune, Inc. | Schafer Klaus | Director | Option Exercise | A | 12.03 | 25,500 | 306,765 | 25,500 | |
Sep 28 2020 | ALT | Altimmune, Inc. | GILL JOHN | Director | Option Exercise | A | 12.03 | 25,500 | 306,765 | 25,500 | |
Aug 31 2020 | ALT | Altimmune, Inc. | Garg Vipin K | President & CEO | Payment of Exercise | F | 17.62 | 2,015 | 35,504 | 323,774 | 325.8 K to 323.8 K (-0.62 %) |
Aug 04 2020 | ALT | Altimmune, Inc. | Harris Matthew Scott | Chief Medical Offic ... | Grant | A | 1.46 | 8,084 | 11,803 | 8,084 | 0 to 8.1 K |
Aug 04 2020 | ALT | Altimmune, Inc. | Brown William Michael | Chief Financial Off ... | Grant | A | 1.46 | 7,920 | 11,563 | 15,981 | 8.1 K to 16 K (+98.25 %) |
Aug 04 2020 | ALT | Altimmune, Inc. | Roberts M Scot | Chief Scientific Of ... | Grant | A | 1.46 | 3,859 | 5,634 | 9,394 | 5.5 K to 9.4 K (+69.72 %) |
Aug 04 2020 | ALT | Altimmune, Inc. | Garg Vipin K | Chief Financial Off ... | Grant | A | 1.46 | 11,674 | 17,044 | 325,789 | 314.1 K to 325.8 K (+3.72 %) |
Aug 03 2020 | ALT | Altimmune, Inc. | Garg Vipin K | President and CEO | Payment of Exercise | F | 26.06 | 2,015 | 52,511 | 314,115 | 316.1 K to 314.1 K (-0.64 %) |
Jul 01 2020 | ALT | Altimmune, Inc. | Garg Vipin K | President and CEO | Payment of Exercise | F | 10.71 | 2,015 | 21,581 | 316,130 | 318.1 K to 316.1 K (-0.63 %) |
Jun 29 2020 | ALT | Altimmune, Inc. | Drutz David | Director | Option Exercise | A | 0.00 | 16,850 | 0 | 16,850 | |
Jun 29 2020 | ALT | Altimmune, Inc. | Hodges Philip | Director | Option Exercise | A | 0.00 | 16,850 | 0 | 16,850 | |
Jun 29 2020 | ALT | Altimmune, Inc. | Schafer Klaus | Director | Option Exercise | C | 0.00 | 16,850 | 0 | 16,850 | |
Jun 29 2020 | ALT | Altimmune, Inc. | GILL JOHN | Director | Option Exercise | A | 0.00 | 16,850 | 0 | 16,850 | |
Jun 29 2020 | ALT | Altimmune, Inc. | SAYARE MITCHEL | Director | Option Exercise | A | 0.00 | 25,275 | 0 | 25,275 | |
Jun 29 2020 | ALT | Altimmune, Inc. | Pisano Wayne | Director | Option Exercise | A | 0.00 | 16,850 | 0 | 16,850 | |
Jun 29 2020 | ALT | Altimmune, Inc. | GILL JOHN | Director | Option Exercise | A | 0.00 | 16,850 | 0 | 16,850 | |
Jun 29 2020 | ALT | Altimmune, Inc. | SAYARE MITCHEL | Director | Option Exercise | A | 0.00 | 25,275 | 0 | 25,275 | |
Jun 29 2020 | ALT | Altimmune, Inc. | Pisano Wayne | Director | Option Exercise | A | 0.00 | 16,850 | 0 | 16,850 | |
Jun 15 2020 | ALT | Altimmune, Inc. | Venrock Healthcare Capital Par ... | 10% Owner | Buy | P | 7.54 | 1,500,000 | 11,310,000 | 4,500,000 | 3 M to 4.5 M (+50.00 %) |
Jun 02 2020 | ALT | Altimmune, Inc. | Garg Vipin K | President and CEO | Payment of Exercise | F | 9.28 | 2,015 | 18,699 | 318,145 | 320.2 K to 318.1 K (-0.63 %) |
May 28 2020 | ALT | Altimmune, Inc. | Venrock Healthcare Capital Par ... | 10% Owner | Buy | P | 8.87 | 173,711 | 1,540,817 | 3,000,000 | 2.8 M to 3 M (+6.15 %) |
May 28 2020 | ALT | Altimmune, Inc. | Venrock Healthcare Capital Par ... | 10% Owner | Buy | P | 7.79 | 27,763 | 216,274 | 2,826,289 | 2.8 M to 2.8 M (+0.99 %) |
May 28 2020 | ALT | Altimmune, Inc. | Venrock Healthcare Capital Par ... | 10% Owner | Buy | P | 7.92 | 277,000 | 2,193,840 | 2,798,526 | 2.5 M to 2.8 M (+10.99 %) |
May 28 2020 | ALT | Altimmune, Inc. | Venrock Healthcare Capital Par ... | 10% Owner | Buy | P | 7.23 | 125,162 | 904,921 | 2,521,526 | 2.4 M to 2.5 M (+5.22 %) |
May 28 2020 | ALT | Altimmune, Inc. | Venrock Healthcare Capital Par ... | 10% Owner | Buy | P | 9.78 | 390,547 | 3,819,550 | 2,396,364 | 2 M to 2.4 M (+19.47 %) |
May 28 2020 | ALT | Altimmune, Inc. | Venrock Healthcare Capital Par ... | 10% Owner | Buy | P | 8.79 | 309,453 | 2,720,092 | 2,005,817 | 1.7 M to 2 M (+18.24 %) |
May 18 2020 | ALT | Altimmune, Inc. | VELOCITY PHARMACEUTICAL HOLDIN ... | 10% Owner | Sell | S | 4.65 | 30,622 | 142,392 | 1,687,250 | 1.7 M to 1.7 M (-1.78 %) |
May 18 2020 | ALT | Altimmune, Inc. | VELOCITY PHARMACEUTICAL HOLDIN ... | 10% Owner | Sell | S | 4.81 | 169,378 | 814,708 | 1,717,872 | 1.9 M to 1.7 M (-8.97 %) |
May 12 2020 | ALT | Altimmune, Inc. | Jorkasky Diane | Director | Option Exercise | A | 3.15 | 40,000 | 126,000 | 40,000 | |
May 04 2020 | ALT | Altimmune, Inc. | Garg Vipin K | President and CEO | Payment of Exercise | F | 3.05 | 2,015 | 6,146 | 320,160 | 322.2 K to 320.2 K (-0.63 %) |
Apr 01 2020 | ALT | Altimmune, Inc. | Garg Vipin K | President and CEO | Payment of Exercise | F | 3.02 | 2,016 | 6,088 | 322,175 | 324.2 K to 322.2 K (-0.62 %) |
Feb 04 2020 | ALT | Altimmune, Inc. | Brown William Michael | Chief Financial Off ... | Grant | A | 1.46 | 8,061 | 11,769 | 8,061 | 0 to 8.1 K |
Feb 04 2020 | ALT | Altimmune, Inc. | Garg Vipin K | President and CEO | Grant | A | 1.46 | 11,289 | 16,482 | 326,206 | 314.9 K to 326.2 K (+3.58 %) |
Feb 04 2020 | ALT | Altimmune, Inc. | Roberts M Scot | Chief Scientific Of ... | Grant | A | 1.46 | 3,698 | 5,399 | 5,535 | 1.8 K to 5.5 K (+201.31 %) |
Feb 03 2020 | ALT | Altimmune, Inc. | Garg Vipin K | President and CEO | Payment of Exercise | F | 1.77 | 2,015 | 3,567 | 314,917 | 316.9 K to 314.9 K (-0.64 %) |
Jan 03 2020 | ALT | Altimmune, Inc. | Roberts M Scot | Chief Scientific Of ... | Option Exercise | A | 1.92 | 61,400 | 117,968 | 61,400 | |
Jan 03 2020 | ALT | Altimmune, Inc. | Garg Vipin K | President and CEO | Option Exercise | A | 1.92 | 149,500 | 287,234 | 149,500 | |
Jan 02 2020 | ALT | Altimmune, Inc. | Garg Vipin K | President and CEO | Payment of Exercise | F | 1.80 | 1,999 | 3,598 | 316,932 | 318.9 K to 316.9 K (-0.63 %) |
Dec 03 2019 | ALT | Altimmune, Inc. | Garg Vipin K | President and CEO | Payment of Exercise | F | 1.82 | 23,976 | 43,636 | 318,931 | 342.9 K to 318.9 K (-6.99 %) |
Sep 11 2019 | ALT | Altimmune, Inc. | Harris Matthew Scott | Chief Medical Offic ... | Option Exercise | A | 2.13 | 107,000 | 227,910 | 107,000 | |
Sep 05 2019 | ALT | Altimmune, Inc. | Garg Vipin K | President and CEO | Buy | P | 2.10 | 20,000 | 42,000 | 342,907 | 322.9 K to 342.9 K (+6.19 %) |
Jun 19 2019 | ALT | Altimmune, Inc. | Tasker Sybil | Chief Medical Offic ... | Option Exercise | A | 2.46 | 20,000 | 49,200 | 20,000 | |
Jun 12 2019 | ALT | Altimmune, Inc. | Brown William Michael | Chief Financial Off ... | Option Exercise | A | 2.34 | 50,000 | 117,000 | 50,000 | |
Mar 27 2019 | ALT | Altimmune, Inc. | Tasker Sybil | Chief Medical Offic ... | Option Exercise | A | 2.95 | 38,000 | 112,100 | 38,000 | |
Mar 27 2019 | ALT | Altimmune, Inc. | Roberts M Scot | Chief Scientific Of ... | Option Exercise | A | 2.95 | 38,000 | 112,100 | 38,000 | |
Jan 04 2019 | ALT | Altimmune, Inc. | Brown William Michael | Acting Chief Financ ... | Option Exercise | A | 2.60 | 30,000 | 78,000 | 30,000 | |
Jan 04 2019 | ALT | Altimmune, Inc. | SAYARE MITCHEL | Director | Option Exercise | A | 2.60 | 30,000 | 78,000 | 30,000 | |
Jan 04 2019 | ALT | Altimmune, Inc. | Schafer Klaus | Director | Option Exercise | A | 2.60 | 20,000 | 52,000 | 20,000 | |
Jan 04 2019 | ALT | Altimmune, Inc. | Hodges Philip | Director | Option Exercise | A | 2.60 | 20,000 | 52,000 | 20,000 | |
Jan 04 2019 | ALT | Altimmune, Inc. | GILL JOHN | Director | Option Exercise | A | 2.60 | 20,000 | 52,000 | 20,000 | |
Jan 04 2019 | ALT | Altimmune, Inc. | Drutz David | Director | Option Exercise | A | 2.60 | 20,000 | 52,000 | 20,000 | |
Jan 04 2019 | ALT | Altimmune, Inc. | Pisano Wayne | Director | Option Exercise | A | 2.60 | 20,000 | 52,000 | 20,000 | |
Jan 04 2019 | ALT | Altimmune, Inc. | Roberts M Scot | Chief Scientific Of ... | Option Exercise | A | 2.60 | 30,000 | 78,000 | 30,000 | |
Dec 04 2018 | ALT | Altimmune, Inc. | Garg Vipin K | President and CEO | Option Exercise | A | 3.59 | 111,421 | 400,001 | 111,421 | |
Dec 04 2018 | ALT | Altimmune, Inc. | Garg Vipin K | President and CEO | Option Exercise | A | 3.59 | 211,486 | 759,235 | 211,486 | |
Dec 04 2018 | ALT | Altimmune, Inc. | Garg Vipin K | President and CEO | Grant | A | 0.00 | 322,907 | 0 | 322,907 | 0 to 322.9 K |
Oct 11 2018 | ALT | Altimmune, Inc. | Pisano Wayne | Director | Buy | P | 4.59 | 2,000 | 9,180 | 2,000 | 0 to 2 K |
Sep 14 2018 | ALT | Altimmune, Inc. | Novartis Bioventures Ltd | 10% Owner | Option Exercise | J | 2.67 | 465,086 | 1,241,780 | 0 | |
Sep 14 2018 | ALT | Altimmune, Inc. | Novartis Bioventures Ltd | 10% Owner | Buy | J | 0.00 | 2,069,993 | 0 | 8,345,145 | 6.3 M to 8.3 M (+32.99 %) |
Jul 13 2018 | ALT | Altimmune, Inc. | Novartis Bioventures Ltd | 10% Owner | Option Exercise | J | 2.67 | 345 | 921 | 0 | |
Jul 13 2018 | ALT | Altimmune, Inc. | Novartis Bioventures Ltd | 10% Owner | Buy | J | 0.00 | 663,346 | 0 | 6,275,152 | 5.6 M to 6.3 M (+11.82 %) |
Jun 19 2018 | ALT | Altimmune, Inc. | Novartis Bioventures Ltd | 10% Owner | Buy | J | 0.00 | 14,449 | 0 | 5,611,806 | 5.6 M to 5.6 M (+0.26 %) |
Jun 15 2018 | ALT | Altimmune, Inc. | Novartis Bioventures Ltd | 10% Owner | Option Exercise | J | 2.67 | 345 | 921 | 345 | |
Jun 15 2018 | ALT | Altimmune, Inc. | Novartis Bioventures Ltd | 10% Owner | Buy | J | 0.00 | 720,878 | 0 | 5,597,357 | 4.9 M to 5.6 M (+14.78 %) |
May 29 2018 | ALT | Altimmune, Inc. | Enright William | President and CEO | Buy | P | 0.51 | 1,300 | 660 | 365,839 | 364.5 K to 365.8 K (+0.36 %) |
May 23 2018 | ALT | Altimmune, Inc. | Tasker Sybil | Chief Medical Offic ... | Option Exercise | A | 0.45 | 50,016 | 22,257 | 50,016 | |
May 23 2018 | ALT | Altimmune, Inc. | Roberts M Scot | Chief Scientific Of ... | Option Exercise | M | 0.08 | 55,120 | 4,410 | 0 | |
May 23 2018 | ALT | Altimmune, Inc. | Roberts M Scot | Chief Scientific Of ... | Option Exercise | A | 0.45 | 50,016 | 22,257 | 50,016 | |
May 23 2018 | ALT | Altimmune, Inc. | Roberts M Scot | Chief Scientific Of ... | Buy | M | 0.08 | 55,120 | 4,410 | 55,120 | 0 to 55.1 K |
May 23 2018 | ALT | Altimmune, Inc. | Enright William | President and CEO | Option Exercise | A | 0.45 | 103,158 | 45,905 | 103,158 | |
May 17 2018 | ALT | Altimmune, Inc. | Novartis Bioventures Ltd | 10% Owner | Option Exercise | J | 2.67 | 345 | 921 | 690 | |
May 17 2018 | ALT | Altimmune, Inc. | Novartis Bioventures Ltd | 10% Owner | Buy | J | 0.00 | 767,728 | 0 | 4,876,479 | 4.1 M to 4.9 M (+18.69 %) |
May 17 2018 | ALT | Altimmune, Inc. | Novartis Bioventures Ltd | 10% Owner | Buy | J | 0.00 | 274,703 | 0 | 4,108,751 | 3.8 M to 4.1 M (+7.16 %) |
Apr 18 2018 | ALT | Altimmune, Inc. | Novartis Bioventures Ltd | 10% Owner | Option Exercise | J | 2.67 | 345 | 921 | 1,035 | |
Apr 18 2018 | ALT | Altimmune, Inc. | Novartis Bioventures Ltd | 10% Owner | Buy | J | 0.00 | 217,159 | 0 | 3,834,048 | 3.6 M to 3.8 M (+6.00 %) |
Apr 18 2018 | ALT | Altimmune, Inc. | Novartis Bioventures Ltd | 10% Owner | Buy | J | 0.00 | 482,907 | 0 | 3,616,889 | 3.1 M to 3.6 M (+15.41 %) |
Apr 06 2018 | ALT | Altimmune, Inc. | SAYARE MITCHEL | Director | Option Exercise | A | 0.95 | 35,000 | 33,250 | 35,000 | |
Mar 19 2018 | PIP | Altimmune, Inc. | Novartis Bioventures Ltd | 10% Owner | Option Exercise | J | 2.67 | 345 | 921 | 1,380 | |
Mar 19 2018 | PIP | Altimmune, Inc. | Novartis Bioventures Ltd | 10% Owner | Buy | J | 0.00 | 261,969 | 0 | 3,133,982 | 2.9 M to 3.1 M (+9.12 %) |
Feb 23 2018 | PIP | Altimmune, Inc. | Roberts M Scot | Chief Scientific Of ... | Buy | P | 4.42 | 449 | 1,985 | 449 | 0 to 449 |
Feb 15 2018 | PIP | Altimmune, Inc. | Truffle Capital S.A.S. | 10% Owner | Option Exercise | J | 2.67 | 23 | 61 | 114 | |
Feb 15 2018 | PIP | Altimmune, Inc. | Truffle Capital S.A.S. | 10% Owner | Option Exercise | J | 2.67 | 30 | 80 | 152 | |
Feb 15 2018 | PIP | Altimmune, Inc. | Truffle Capital S.A.S. | 10% Owner | Option Exercise | J | 2.67 | 23 | 61 | 114 | |
Feb 15 2018 | PIP | Altimmune, Inc. | Truffle Capital S.A.S. | 10% Owner | Buy | J | 0.00 | 4,483 | 0 | 76,700 | 72.2 K to 76.7 K (+6.21 %) |
Feb 15 2018 | PIP | Altimmune, Inc. | Truffle Capital S.A.S. | 10% Owner | Buy | J | 0.00 | 5,977 | 0 | 139,184 | 133.2 K to 139.2 K (+4.49 %) |
Feb 15 2018 | PIP | Altimmune, Inc. | Truffle Capital S.A.S. | 10% Owner | Buy | J | 0.00 | 4,483 | 0 | 179,427 | 174.9 K to 179.4 K (+2.56 %) |
Feb 15 2018 | PIP | Altimmune, Inc. | Truffle Capital S.A.S. | 10% Owner | Buy | J | 0.00 | 17,789 | 0 | 72,217 | 54.4 K to 72.2 K (+32.68 %) |
Feb 15 2018 | PIP | Altimmune, Inc. | Truffle Capital S.A.S. | 10% Owner | Buy | J | 0.00 | 23,719 | 0 | 133,207 | 109.5 K to 133.2 K (+21.66 %) |
Feb 15 2018 | PIP | Altimmune, Inc. | Truffle Capital S.A.S. | 10% Owner | Buy | J | 0.00 | 17,789 | 0 | 174,944 | 157.2 K to 174.9 K (+11.32 %) |
Feb 15 2018 | PIP | Altimmune, Inc. | Novartis Bioventures Ltd | 10% Owner | Option Exercise | J | 2.67 | 345 | 921 | 1,725 | |
Feb 15 2018 | PIP | Altimmune, Inc. | Novartis Bioventures Ltd | 10% Owner | Buy | J | 0.00 | 67,925 | 0 | 2,872,013 | 2.8 M to 2.9 M (+2.42 %) |
Feb 15 2018 | PIP | Altimmune, Inc. | Novartis Bioventures Ltd | 10% Owner | Buy | J | 0.00 | 269,527 | 0 | 2,804,088 | 2.5 M to 2.8 M (+10.63 %) |
Jan 19 2018 | PIP | Altimmune, Inc. | Novartis Bioventures Ltd | 10% Owner | Option Exercise | J | 2.67 | 345 | 921 | 2,070 | |
Jan 19 2018 | PIP | Altimmune, Inc. | Novartis Bioventures Ltd | 10% Owner | Buy | J | 0.00 | 176,586 | 0 | 2,534,561 | 2.4 M to 2.5 M (+7.49 %) |
Jan 19 2018 | PIP | Altimmune, Inc. | Truffle Capital S.A.S. | 10% Owner | Option Exercise | J | 2.67 | 23 | 61 | 137 | |
Jan 19 2018 | PIP | Altimmune, Inc. | Truffle Capital S.A.S. | 10% Owner | Option Exercise | J | 2.67 | 30 | 80 | 182 | |
Jan 19 2018 | PIP | Altimmune, Inc. | Truffle Capital S.A.S. | 10% Owner | Option Exercise | J | 2.67 | 23 | 61 | 137 | |
Jan 19 2018 | PIP | Altimmune, Inc. | Truffle Capital S.A.S. | 10% Owner | Buy | J | 0.00 | 11,655 | 0 | 54,428 | 42.8 K to 54.4 K (+27.25 %) |
Jan 19 2018 | PIP | Altimmune, Inc. | Truffle Capital S.A.S. | 10% Owner | Buy | J | 0.00 | 15,541 | 0 | 109,488 | 93.9 K to 109.5 K (+16.54 %) |
Jan 19 2018 | PIP | Altimmune, Inc. | Truffle Capital S.A.S. | 10% Owner | Buy | J | 0.00 | 11,655 | 0 | 157,155 | 145.5 K to 157.2 K (+8.01 %) |
Jan 04 2018 | PIP | Altimmune, Inc. | Enright William | President and CEO | Option Exercise | M | 0.08 | 183,347 | 14,668 | 0 | |
Jan 04 2018 | PIP | Altimmune, Inc. | Enright William | President and CEO | Buy | M | 0.08 | 183,347 | 14,668 | 364,511 | 181.2 K to 364.5 K (+101.20 %) |
Jan 03 2018 | PIP | Altimmune, Inc. | SAYARE MITCHEL | Director | Buy | P | 1.95 | 5,100 | 9,963 | 32,650 | 27.6 K to 32.7 K (+18.51 %) |
Jan 02 2018 | PIP | Altimmune, Inc. | SCHAFFER DERACE L | Director | Buy | P | 1.93 | 38,699 | 74,778 | 589,453 | 550.8 K to 589.5 K (+7.03 %) |
Jan 02 2018 | PIP | Altimmune, Inc. | SCHAFFER DERACE L | Director | Buy | P | 1.92 | 58,711 | 112,672 | 550,754 | 492 K to 550.8 K (+11.93 %) |
Dec 27 2017 | PIP | Altimmune, Inc. | SCHAFFER DERACE L | Director | Buy | P | 1.77 | 27,706 | 49,040 | 492,043 | 464.3 K to 492 K (+5.97 %) |
Dec 27 2017 | PIP | Altimmune, Inc. | SCHAFFER DERACE L | Director | Buy | P | 1.76 | 50,000 | 88,170 | 464,337 | 414.3 K to 464.3 K (+12.07 %) |
Dec 27 2017 | PIP | Altimmune, Inc. | SCHAFFER DERACE L | Director | Buy | P | 1.81 | 51,442 | 93,269 | 414,337 | 362.9 K to 414.3 K (+14.18 %) |
Dec 27 2017 | PIP | Altimmune, Inc. | SCHAFFER DERACE L | Director | Buy | P | 1.61 | 17,982 | 28,877 | 362,895 | 344.9 K to 362.9 K (+5.21 %) |
Dec 15 2017 | PIP | Altimmune, Inc. | Truffle Capital S.A.S. | 10% Owner | Option Exercise | J | 2.67 | 23 | 61 | 159 | |
Dec 15 2017 | PIP | Altimmune, Inc. | Truffle Capital S.A.S. | 10% Owner | Option Exercise | J | 2.67 | 30 | 80 | 212 | |
Dec 15 2017 | PIP | Altimmune, Inc. | Truffle Capital S.A.S. | 10% Owner | Option Exercise | J | 2.67 | 23 | 61 | 159 | |
Dec 15 2017 | PIP | Altimmune, Inc. | Truffle Capital S.A.S. | 10% Owner | Buy | J | 0.00 | 4,337 | 0 | 42,773 | 38.4 K to 42.8 K (+11.28 %) |
Dec 15 2017 | PIP | Altimmune, Inc. | Truffle Capital S.A.S. | 10% Owner | Buy | J | 0.00 | 5,784 | 0 | 93,947 | 88.2 K to 93.9 K (+6.56 %) |
Dec 15 2017 | PIP | Altimmune, Inc. | Truffle Capital S.A.S. | 10% Owner | Buy | J | 0.00 | 4,337 | 0 | 145,500 | 141.2 K to 145.5 K (+3.07 %) |
Dec 15 2017 | PIP | Altimmune, Inc. | Truffle Capital S.A.S. | 10% Owner | Buy | J | 0.00 | 16,018 | 0 | 38,436 | 22.4 K to 38.4 K (+71.45 %) |